University of Duisburg-Essen

Aviation Capital Group Appoints Vicente Alava Pons Managing Director of Aircraft Financing Solutions

Retrieved on: 
Wednesday, November 1, 2023
Professional Services, Air, Aerospace, Transport, Manufacturing, Finance, Asset Management, Aircraft, Capital Group Companies, MUFG Bank, EVP, AFS, Economics, ACG, University of Duisburg-Essen, Pons, Workplace, DVB Bank, Growth, LR, University, Aviation, Airline

Aviation Capital Group LLC (ACG) today announced that Vicente Alava Pons has joined the company as a Managing Director on the Aircraft Financing Solutions (AFS) team.

Key Points: 
  • Aviation Capital Group LLC (ACG) today announced that Vicente Alava Pons has joined the company as a Managing Director on the Aircraft Financing Solutions (AFS) team.
  • Pons will be based in Europe, supporting the growth of ACG’s AFS business by developing and structuring new creative financing solutions for airlines and lenders worldwide.
  • “Vicente brings innovative perspectives that will play a pivotal role in steering our company towards continued growth and success.
  • "I am excited to join a well-established and world-leading aircraft lessor like ACG and contribute to expanding the Aircraft Financing Solutions group’s business potential,” said Pons.

Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer

Retrieved on: 
Tuesday, September 12, 2023
Oxidative phosphorylation, Pancreatic cancer, NF, University, Cell death, GAPDH, Glomus tumor, ATP, Enzyme, Agonal respiration, Quality of life, Cancer, Research, Ruhr University Bochum, Molecular medicine, University of Duisburg-Essen, Patient, Manuscript, Apoptosis, Organ (biology), Journal of Cellular and Molecular Medicine, ST, Factorization of polynomials, Pharmaceutical industry, Panaveli

BERWYN, PA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the outcomes and quality of life for patients, today announced publication of positive data in the peer-reviewed Journal of Cellular and Molecular Medicine in a manuscript titled, “GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells1.” The publication by Majchrzak-Stiller, et al. (2023) details the multiple sites of action of GP-2250 in the disruption of energy production of cancer cells and the downregulation of tumor promoting transcription factors.

Key Points: 
  • GP-2250 is a highly selective yet broadly active cancer therapeutic with a unique mechanism of action that suppresses cancer by disrupting its energy metabolism, leading to cancer cell death through several validated mechanisms.
  • GP-2250 is currently being studied in a Phase 1 clinical trial for pancreatic cancer.
  • Results of the preclinical study showed that at the lowest dose of GP-2250 tested (250 μM), a significant decrease in ATP was apparent at 6 hours in both pancreatic cancer cell lines.
  • We are pleased with the results GP-2250 demonstrated, and the metabolic and transcriptional findings provide molecular targets for GP-2250.

Acronis' Mid-Year Cyberthreats Report Reveals 464% Increase in Email Attacks

Retrieved on: 
Thursday, June 29, 2023
Cybercrime, Risk, Becs, Attack, University, Blackcat Lake, LLM, TB, ChatGPT, RMM, URL, Crime, DLP, Cyberattack, Organization, Acronis, EDR, Student, Machine learning, AI, University of Duisburg-Essen, Medical device, Cryptocurrency, Risk management, Internet service provider, Online shopping, Research

In the first half of 2023 alone, the number of email-based phishing attacks has surged 464% when compared to 2022.

Key Points: 
  • In the first half of 2023 alone, the number of email-based phishing attacks has surged 464% when compared to 2022.
  • Over the same frame, there has also been a 24% increase in attacks per organization.
  • In the first half of 2023, Acronis-monitored endpoints observed a 15% increase in the number of files and URLs per scanned email.
  • For more information, download a copy of the full Acronis Mid-Year Cyberthreats Report 2023 here: https://www.acronis.com/en-us/resource-center/resource/acronis-mid-year-...
    To learn more about the report and its findings, visit the Acronis blog post .

Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Merkel Cell Carcinoma (MCC)

Retrieved on: 
Thursday, June 29, 2023
Survival rate, STAT3, University, Glomus tumor, Bromodeoxyuridine, Merkel cell polyomavirus, Necrosis, Journal of Cancer Research and Clinical Oncology, Skin cancer, Quality of life, Ruhr University Bochum, University of Duisburg-Essen, AKT, Patient, Manuscript, Cancer, Flow cytometry, MCC, Apoptosis, MTT, Organ (biology), ST, Pharmaceutical industry, Vaccine, Panaveli, Angela Merkel, Erosion (morphology)

BERWYN, Pa., June 29, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the effectiveness of cancer treatments and quality of life for the patients that receive them, today announced the publication of positive preliminary data in a manuscript titled, “The effect of GP‑2250 on cultured virus‑negative Merkel cell carcinoma cells: preliminary results1,” in the peer-reviewed Journal of Cancer Research and Clinical Oncology.

Key Points: 
  • The objective of the preclinical study was to investigate the effects of GP-2250 on Merkel cell polyomavirus (MCPyV)-negative MCC cells.
  • Greg Bosch, Chairman and CEO of Panavance Therapeutics commented, “We are encouraged by these preclinical findings in this rare, aggressive form of skin cancer.
  • This study was able to show that GP-2250 has significant, dose-dependent cytotoxic effects on MCC cells as well as reduced cancer cell proliferation and migration.
  • GP-2250’s effects on cell viability, proliferation and migration were evaluated by means of MTT, BrdU, and scratch assays, respectively.

Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Thursday, May 25, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, GIST, DNA, University, Diarrhea, Progression-free survival, Sunitinib, Survival, OS, Cancer, AP, Toxicity, Associate, PFS, Mutation, Teaching hospital, QD, ASCO, KIT, Hypertension, Hair, Myalgia, American Society of Clinical Oncology, HIV disease progression rates, Patient, Clinical research, Annual general meeting, German Cancer Research Center, University of Duisburg-Essen, Neoplasm, ITT, Gastrointestinal stromal tumor, Society, Alvin J. Siteman Cancer Center, Clinical, ORR, IRR, Safety, Fatigue, Pharmaceutical industry, Medical imaging, Typesetting, Jet fuel, Bookkeeping

“As we prepare to initiate our INSIGHT pivotal Phase 3 study of QINLOCK versus sunitinib in second-line GIST patients with KIT exon 11 and 17/18 mutations, we are excited to share details on the study design and additional supporting data from the INTRIGUE study.

Key Points: 
  • “As we prepare to initiate our INSIGHT pivotal Phase 3 study of QINLOCK versus sunitinib in second-line GIST patients with KIT exon 11 and 17/18 mutations, we are excited to share details on the study design and additional supporting data from the INTRIGUE study.
  • In the all-patient intent-to-treat population, overall survival was 35.5 months in the QINLOCK arm and 30.9 months in the sunitinib arm.
  • The favorable safety profile was consistent with our primary analysis, with fewer patients on QINLOCK experiencing Grade 3/4 treatment-emergent adverse events compared to sunitinib.
  • Presentation details are as follows:
    Title: Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.

Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Retrieved on: 
Tuesday, January 24, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, DNA, German Cancer Research Center, American Society of Clinical Oncology, Trial of the century, GIST, KIT, Neoplasm, Patient, ITT, University, Gastrointestinal stromal tumor, University of Duisburg-Essen, Disease, Society, PFS, Cancer, Circulating tumor DNA, Teaching hospital, ASCO, Pharmaceutical industry

Baseline peripheral whole blood was analyzed by Guardant360, a 74-gene ctDNA next-generation sequencing liquid biopsy assay.

Key Points: 
  • Baseline peripheral whole blood was analyzed by Guardant360, a 74-gene ctDNA next-generation sequencing liquid biopsy assay.
  • Patients with mutations in KIT exon 11 and exon 17/18 only derived substantially improved clinical benefit with QINLOCK versus sunitinib.
  • Patients with mutations in KIT exon 11 and 13/14 only derived substantially improved clinical benefit with sunitinib versus QINLOCK.
  • QINLOCK was generally well-tolerated and the safety profiles were consistent with the primary analysis of the INTRIGUE study.

Panavance Therapeutics Announces Publication of Promising Preclinical Data Evaluating GP-2250 for the Treatment of Malignant Peritoneal Mesothelioma

Retrieved on: 
Monday, August 8, 2022
FDA, Apoptosis, Mesothelioma, Respiration (physiology), CEO, Forward-looking statement, GLOBE, La Trobe Institute for Molecular Science, Population, Breast, Synergy, Cancer, Cisplatin, Flow cytometry, ST, Quality of life, Patient, University of Duisburg-Essen, Therapy, Company, International Journal of Molecular Sciences, Pancreatic cancer, Organ (anatomy), Manuscript, General officer, Canadian International Council, Mitomycin C, Melanoma, University, Ovarian cancer, Ruhr University Bochum, Necrosis, Pharmaceutical industry, Panaveli

BERWYN, Pa., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic designed to disrupt cancer’s energy metabolism and improve quality of life for patients, today announced the publication of positive preclinical data from a 3-D in vitro study evaluating GP-2250 for the treatment of malignant peritoneal mesothelioma. The manuscript titled, “Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma—A 3-D In Vitro Study1,” was published in the peer-reviewed journal, International Journal of Molecular Sciences. 

Key Points: 
  • This preclinical study is the first to investigate effects of the novel agent GP-2250 on malignant mesothelioma.
  • As we progress its development for the treatment of pancreatic ductal adenocarcinoma, amassing a growing body of data provides valuable validation and guidance.
  • We look forward to further exploring the potential of GP-2250, commented Greg Bosch, Chairman and CEO of Panavance Therapeutics.
  • GP-2250 showed promising antineoplastic effects on malignant mesothelioma cells in vitro especially in combination with cisplatin/mitomycin C even when used at lower concentrations.

Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Pancreatic Neuroendocrine Carcinoma

Retrieved on: 
Thursday, June 9, 2022
Gemcitabine, Company, University of Duisburg-Essen, AG, Survival, Forward-looking statement, CEO, University Hospitals of the Ruhr-University of Bochum, Pancreatic neuroendocrine tumor, Hope, Ovarian cancer, University, Respiration (physiology), Ed, ST, Therapy, FDA, Development, Manuscript, GLOBE, Patient, Chemische Industrie Uithoorn, Incidence, Quality of life, Industry, Organ (anatomy), Wilms' tumor, General officer, PDX, Immortalised cell line, RECIST, Pancreas, Pharmaceutical industry, Panaveli, Cancer

BERWYN, Pa., June 09, 2022 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic designed to disrupt cancer’s energy metabolism and improve quality of life for patients, today announced the publication of positive data from a preclinical study evaluating GP-2250 for the treatment of pancreatic neuroendocrine carcinoma. The manuscript titled, “New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo1,” was published in the peer-reviewed journal, Cancers. 

Key Points: 
  • Neuroendocrine carcinoma of the pancreas is an aggressive form of neuroendocrine tumors which continue to increase in incidence but not in survival rates.
  • This study was the first to evaluate the effects of GP-2250 on pancreatic neuroendocrine tumors and we are very pleased with the encouraging results demonstrated.
  • This additional analysis suggests that GP-2250 may be valuable not only in pancreatic ductal adenocarcinoma but also in pancreatic neuroendocrine tumors.
  • Panavance is initially advancing development of GP-2250 for the treatment of pancreatic ductal adenocarcinoma cancer, and has active preclinical studies in numerous other cancers including ovarian cancer.

DGAP-News: Gerresheimer AG: Annual General Meeting of Gerresheimer AG approves dividend of EUR 1.25 per share following a successful financial year – Gradual renewal of Supervisory Board initiated

Retrieved on: 
Wednesday, June 8, 2022
Audit committee, University of Duisburg-Essen, CEO, Policy, Annual general meeting, Investment, University, Annual, Supervisory board, Chairperson, National Executive Board of the Boy Scouts of America, Supervision, Committee, EUR, Board, Board of directors, Property management

Duesseldorf, June 08, 2022 The Annual General Meeting of Gerresheimer AG has approved the payment of a dividend of EUR 1.25 per share for the 2021 financial year.

Key Points: 
  • Duesseldorf, June 08, 2022 The Annual General Meeting of Gerresheimer AG has approved the payment of a dividend of EUR 1.25 per share for the 2021 financial year.
  • The dividend of EUR 1.25 per share represents a payout ratio of 30 percent of the companys adjusted net income.
  • The Annual General Meeting approved the concept of a gradual renewal of the Supervisory Board.
  • The long and commendable membership of her predecessor on the Supervisory Board, Theodor Stuth, ended at the close of the Annual General Meeting.

Cambium Assessment Honored as a Grand Prize Winner in The Nation’s Report Card’s Inaugural Automated Scoring Challenge

Retrieved on: 
Tuesday, February 15, 2022
Primary, Secondary, Education, Technology, Other Technology, Software, Other Education, National Assessment of Educational Progress, National Center for Education Statistics, University of Massachusetts Amherst, NAEP, Psychometrics, Explainable artificial intelligence, University of Duisburg-Essen, Education, Solution, Technical report, Cambium Learning Group, Technology, Learning, Student, LinkedIn, Element, Twitter, NCES, Measurement Incorporated, K-12, Research, Assessment, National Center for Assessment in Higher Education, University, Customer service, Toy, Cambium, Facebook

Cambium Assessment, Inc. , a Cambium Learning Group company, announced today that it is a grand prize winner in the National Center for Education Statistics (NCES) inaugural automated scoring challenge .

Key Points: 
  • Cambium Assessment, Inc. , a Cambium Learning Group company, announced today that it is a grand prize winner in the National Center for Education Statistics (NCES) inaugural automated scoring challenge .
  • NCES, which administers the National Assessment of Educational Progress (NAEP), also known as The Nations Report Card, launched its first automated scoring challenge in 2021, awarding four grand prizes and recognizing four runner-up teams.
  • Cambium Assessment is a grand prize winner in the item-specific part of the challenge as well as a runner-up in the generic portion, where automated scoring models were trained without access to the item data.
  • The Cambium family of brands includes: Cambium Assessment, Lexia Learning, Learning A-Z, Voyager Sopris Learning, ExploreLearning, Time4Learning, and Kurzweil Education.